Search

Search Constraints

You searched for: Author/Creator Suda, G.

Search Results

1. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population. (December 2022)

2. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. (December 2022)

3. Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C. Issue 12 (29th July 2017)

4. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib. (March 2023)